The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes.

Abstract

Traditional phase I studies find the therapeutic dose of an investigational drug based solely on toxicity and without regard to the drug's efficacy. We propose extending the continual reassessment method (CRM) to a bivariate trial design in which the maximum tolerated dose is based jointly on both toxicity and disease progression. We call our study design… (More)

Topics

Cite this paper

@article{Braun2002TheBC, title={The bivariate continual reassessment method. extending the CRM to phase I trials of two competing outcomes.}, author={Thomas M. Braun}, journal={Controlled clinical trials}, year={2002}, volume={23 3}, pages={240-56} }